Estimating progression to cirrhosis in chronic hepatitis C virus infection

Hepatology

Volumn 34, Issue 4 I, 2001, Pages 809-816

  Freeman, Anthony J ^a   Dore, Gregory J ^b   Law, Matthew G ^b   Thorpe, Max ^c   Von Overbeck, Jan ^c   Lloyd, Andrew R ^d   Marinos, George ^a   Kaldor, John M ^b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Swiss Re   (Switzerland)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ALCOHOL CONSUMPTION; ARTICLE; DISEASE COURSE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE;

EID: 0034802218     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.27831     Document Type: Article

References (71)

1. Pathogenesis, natural history, treatment, and prevention of hepatitis C
2. Natural history of hepatitis C
3. Epidemiology and long term prognosis of hepatitis C virus infection in Japan
4. Clinical outcomes after transfusion-associated hepatitis C
5. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975
6. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study
7. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening
8. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
9. The natural history of hepatitis C virus infection: Host, viral, and environmental factors
10. Modeling the hepatitis C virus epidemic in France
11. Classification of chronic hepatitis: Diagnosis, grading and staging
12. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection
13. Which patients with hepatitis C develop liver complications?
14. Histological patterns of prolonged hepatitis C infection
15. Risk factors and predictors of outcome in an Australian cohort with hepatitis C virus infection
16. Severity of liver disease in hepatitis C infection contracted through injecting drug use
17. Serum aminotransferase levels and histological disease in chronic hepatitis C
18. Hepatitis C virus genotypes: Epidemiological and clinical associations
19. Natural history of liver fibrosis progression in patients with chronic hepatitis C
20. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French survey of 6,664 patients
21. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C
22. Determinants of outcome of compensated hepatitis C virus-related cirrhosis
23. Distribution of hepatitis C virus genotypes in German patients with chronic hepatitis C: Correlation with clinical and virological parameters
24. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study
25. Factors associated with severity and disease progression in chronic hepatitis C
26. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities
27. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis
28. Serum and liver HCV RNA levels in patients with chronic hepatitis C: Correlation with clinical and histological features
29. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus
30. Quantitative analysis of hepatitis C virus RNA: Relationship between the replicative level and the various stages of the carrier states or the response to interferon therapy
31. Natural course of chronic hepatitis C
32. Histological evolution of chronic hepatitis C. Factors related to progression
33. Epidemiological risk factors and clinico-pathological presentation in chronic hepatitis C
34. Factors associated with cirrhosis development in chronic hepatitis C patients from an area of low prevalence
35. Relationships between serum aminotransferase levels, liver histologies and virological status in patients with chronic hepatitis C in Taiwan
36. Liver histology in hepatitis C infection: A comparison between patients with persistently normal or abnormal transaminases
37. Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients
38. Assessment of liver histology in patients with hepatitis C and normal transaminase levels
39. Importance of age in chronic hepatitis C virus infection
40. Chronic hepatitis C with normal aminotransferase levels: A clinical histologic study
41. Impact of alcohol on the histological and clinical progression of hepatitis C infection
42. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis
43. Late seroconversion and high chronicity rate of hepatitis C virus infection in patients with hematologic disorders
44. Long-term mortality after transfusion-associated non-A, non-B hepatitis
45. Long-term morbidity and mortality of transfusion-associated hepatitis C
46. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis
47. Non-A, non-B post-transfusion hepatitis. Looking back in the second decade
48. Prevalence, severity, and risk factors of liver disease in blood donors positive in a second-generation anti-hepatitis C virus screening test
49. Serum hepatitis C virus RNA levels and liver injury in volunteer blood donors
50. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus
51. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction
52. Hepatitis C virus infection in Spanish volunteer blood donors: HCV RNA analysis and liver disease
53. Epidemiology, serological markers, and hepatic disease of anti-HCV ELISA-2-positive blood donors
54. HCV genotypes in Swedish blood donors as correlated to epidemiology, liver disease and hepatitis C virus antibody profile
55. Chronic hepatitis in United Kingdom blood donors infected with hepatitis C virus
56. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection
57. Hepatitis C in asymptomatic blood donors
58. Volunteer blood donors with antibody to hepatitis C virus: Clinical, biochemical, virologic, and histologic features
59. Assessment of long-term outcomes of hepatitis C virus infection in a cohort of patients with acute hepatitis in 1971-1975: Results of a pilot study
60. Prevalence of chronic liver disease in the general population of northern Italy: The Dionysos Study
61. A retrospective study of hepatitis C virus carriers in a local endemic town in Japan. A possible presence of asymptomatic carrier
62. Outcome of acute symptomatic non-A, non-B hepatitis: A 13-year follow-up study of hepatitis C virus markers
63. The natural history of community-acquired hepatitis C in the United States
64. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study
65. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
66. The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values
67. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
68. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection
69. Consensus among consensus conferences on management of hepatitis C: What we knew then and are still sure about, what we are newly sure about, and what we still need to know
70. 45-Year follow-up of hepatitis C virus infection in healthy young adults
71. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C